ArticleFrontiers in immunology2026
Dysregulated hyaluronan metabolism drives inflammation and angiogenesis in proliferative diabetic retinopathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the expression levels of enzymes and receptors of the hyaluronan (HA) pathway, including HA synthase (HAS)-2, hyaluronidase (Hyal)-1, Hyal-2, CD44 and receptor for HA-mediated motility (RHAMM) in the ocular microenvironment of patients with proliferative diabetic retinopathy (PDR) and the role of HA pathway in inflammation and angiogenesis that drive PDR initiation and progression. Methods: Epiretinal fibrovascular membranes from PDR patients, vitreous samples from PDR and nondiabetic patients, rat retinas, retinal Müller glial cells and human retinal microvascular endothelial cells (HRMECs) were studied by immunohistochemistry, ELISA, Western blot analysis and spectrofluorometric analysis. Functional studies included evaluation of Results: HA, HAS2, Hyal-1, Hyal-2, CD44, syndecan-1 and heparan sulphate levels were upregulated in PDR vitreous samples. Immunohistochemical analysis revealed expression of HAS2, Hyal-2, CD44 and RHAMM in epiretinal membranes, with significant positive correlations between angiogenic activity and HAS2, Hyal-2 and CD44 expression. Diabetes upregulated Hyal-1, CD44, RHAMM and reactive oxygen species in rat retinas. Intravitreal administration of ultralow molecular weight HA (ULMW-HA) in normal adult rats increased retinal vascular permeability and induced upregulation of phospho-NF-κB, phospho-ERK1/2, VEGF, HMGB1, ICAM-1 and VCAM-1 protein levels. In Müller cell cultures, ULMW-HA induced upregulation of phospho-ERK1/2, phospho-NF-κB, HMGB1, VEGF, angiopoietin-2 and MCP-1/CCL2 proteins. The ERK1/2 inhibitor U-0126 and the NF-κB inhibitor BAY11-7085 attenuated ULMW-HA-induced upregulation of VEGF, angiopoietin-2 and MCP-1/CCL2 levels. The hyaluronidase inhibitor apigenin reduced the levels of VEGF and MCP-1/CCL2 induced by diabetic mimetic conditions. In cultured HRMECs, ULMW-HA induced cell migration, whereas apigenin attenuated shedding of soluble syndecan-1 induced by diabetic mimetic conditions and reduced TNF-α-induced upregulation of ICAM-1, VCAM-1 and adherence of monocytes. Conclusions: Abnormal HA metabolism is involved in diabetes-induced retinal endothelial dysfunction and ULMW-HA drives inflammation and angiogenesis in PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.